Reduced Skeletal Muscle Uncoupling Protein-3 Content in Prediabetic Subjects and Type 2 Diabetic Patients: Restoration by Rosiglitazone Treatment | Zendy

Patrick Schrauwen | Zendy; Marco Mensink | Zendy; Gert Schaart | Zendy; Esther MoonenKornips | Zendy; Jean-Pierre Sels | Zendy; Ellen E. Blaak | Zendy; Aaron P. Russell | Zendy; Matthijs K. C. Hesselink | Zendy

Open Access

Reduced Skeletal Muscle Uncoupling Protein-3 Content in Prediabetic Subjects and Type 2 Diabetic Patients: Restoration by Rosiglitazone Treatment

Author(s) -

Patrick Schrauwen,

Marco Mensink,

Gert Schaart,

Esther MoonenKornips,

Jean-Pierre Sels,

Ellen E. Blaak,

Aaron P. Russell,

Matthijs K. C. Hesselink

Publication year - 2006

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2005-1572

Subject(s) - ucp3 , medicine , endocrinology , rosiglitazone , uncoupling protein , insulin resistance , type 2 diabetes , skeletal muscle , diabetes mellitus , impaired glucose tolerance , body mass index , insulin , obesity , brown adipose tissue

The mitochondrial uncoupling protein-3 (UCP3) has been implicated in the protection of the mitochondrial matrix against lipid-induced mitochondrial damage. Recent evidence points toward mitochondrial aberrations as a major contributor to the development of insulin resistance and diabetes, and UCP3 is reduced in diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research